MARKET

TYME

TYME

Tyme Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.330
-0.090
-6.34%
Pre Market: 1.350 +0.02 +1.50% 09:06 04/21 EDT
OPEN
1.440
PREV CLOSE
1.420
HIGH
1.445
LOW
1.330
VOLUME
2.03K
TURNOVER
--
52 WEEK HIGH
4.990
52 WEEK LOW
0.8500
MARKET CAP
226.67M
P/E (TTM)
-6.0953
1D
5D
1M
3M
1Y
5Y
Insider Sells Tyme Technologies Shares
 
Benzinga · 04/07 17:09
8-K: TYME TECHNOLOGIES, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/01 16:38
TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr....
BusinessWire · 04/01 12:00
Best Penny Stocks To Buy Right Now? 4 Biotech Stocks To Watch
Mar 30, 2021 (Penny Stocks via COMTEX) -- Biotech Penny Stocks That Investors are Watching Right Now In the past year, some investors believe that biotech...
Penny Stocks · 03/30 19:43
Top Penny Stocks Under $3 To Watch This Week
Mar 15, 2021 (Penny Stocks via COMTEX) -- Will These 4 Penny Stocks Keep Up Their Bullishness This Week? Penny stocks have been on a bullish journey this...
Penny Stocks · 03/15 19:18
Is Tyme Technologies, Inc.'s (NASDAQ:TYME) Shareholder Ownership Skewed Towards Insiders?
The big shareholder groups in Tyme Technologies, Inc. ( NASDAQ:TYME ) have power over the company. Insiders often own a...
Simply Wall St. · 03/15 14:38
4 High-Volume Penny Stocks For Your March Watch List
Mar 09, 2021 (Penny Stocks via COMTEX) -- Penny Stocks to Watch As Markets Try To Recover With major blue-chip stocks pushing up by big numbers on Tuesday,...
Penny Stocks · 03/10 02:01
Best Stocks To Buy Right Now? 4 To Watch Next Week
Feb 24, 2021 (Penny Stocks via COMTEX) -- Penny Stocks To Watch Next Week As we end another week in February, investors are continuously searching for the...
Penny Stocks · 02/24 21:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TYME. Analyze the recent business situations of Tyme Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TYME stock price target is 9.50 with a high estimate of 9.50 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 106
Institutional Holdings: 17.09M
% Owned: 10.03%
Shares Outstanding: 170.43M
TypeInstitutionsShares
Increased
16
1.02M
New
11
120.01K
Decreased
14
945.70K
Sold Out
6
2.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Chairman/Chief Scientific Officer/Director
Steve Hoffman
Chief Executive Officer/Director
Richard Cunningham
Chief Financial Officer/Chief Accounting Officer/Controller
Barbara Galaini
Chief Operating Officer
Michele Korfin
Other
Giuseppe Del Priore
Other
Jonathan Eckard
Secretary
James Biehl
Independent Director
David Carberry
Independent Director
Donald Degolyer
Independent Director
Douglas Michels
Independent Director
Gerald Sokol
Independent Director
Paul Sturman
Independent Director
Timothy Tyson
No Data
About TYME
TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.

Webull offers kinds of Tyme Technologies Inc stock information, including NASDAQ:TYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYME stock methods without spending real money on the virtual paper trading platform.